These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 27503857

  • 1. SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling.
    Siljamäki E, Abankwa D.
    Mol Cell Biol; 2016 Oct 15; 36(20):2612-25. PubMed ID: 27503857
    [Abstract] [Full Text] [Related]

  • 2. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
    Hirata Y, Brems H, Suzuki M, Kanamori M, Okada M, Morita R, Llano-Rivas I, Ose T, Messiaen L, Legius E, Yoshimura A.
    J Biol Chem; 2016 Feb 12; 291(7):3124-34. PubMed ID: 26635368
    [Abstract] [Full Text] [Related]

  • 3. Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR.
    Yan W, Markegard E, Dharmaiah S, Urisman A, Drew M, Esposito D, Scheffzek K, Nissley DV, McCormick F, Simanshu DK.
    Cell Rep; 2020 Jul 21; 32(3):107909. PubMed ID: 32697994
    [Abstract] [Full Text] [Related]

  • 4. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
    Brems H, Legius E.
    Keio J Med; 2013 Jul 21; 62(4):107-12. PubMed ID: 24334617
    [Abstract] [Full Text] [Related]

  • 5. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.
    Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernández H, Burlingame AL, McCormick F.
    Genes Dev; 2012 Jul 01; 26(13):1421-6. PubMed ID: 22751498
    [Abstract] [Full Text] [Related]

  • 6. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.
    Pasmant E, Gilbert-Dussardier B, Petit A, de Laval B, Luscan A, Gruber A, Lapillonne H, Deswarte C, Goussard P, Laurendeau I, Uzan B, Pflumio F, Brizard F, Vabres P, Naguibvena I, Fasola S, Millot F, Porteu F, Vidaud D, Landman-Parker J, Ballerini P.
    Oncogene; 2015 Jan 29; 34(5):631-8. PubMed ID: 24469042
    [Abstract] [Full Text] [Related]

  • 7. Review and update of SPRED1 mutations causing Legius syndrome.
    Brems H, Pasmant E, Van Minkelen R, Wimmer K, Upadhyaya M, Legius E, Messiaen L.
    Hum Mutat; 2012 Nov 29; 33(11):1538-46. PubMed ID: 22753041
    [Abstract] [Full Text] [Related]

  • 8. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
    Führer S, Tollinger M, Dunzendorfer-Matt T.
    J Mol Biol; 2019 Sep 06; 431(19):3889-3899. PubMed ID: 31401120
    [Abstract] [Full Text] [Related]

  • 9. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.
    Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P, Thomas G, Yoshimura A, Legius E.
    Nat Genet; 2007 Sep 06; 39(9):1120-6. PubMed ID: 17704776
    [Abstract] [Full Text] [Related]

  • 10. Cell type-specific importance of ras-c-raf complex association rate constants for MAPK signaling.
    Kiel C, Serrano L.
    Sci Signal; 2009 Jul 28; 2(81):ra38. PubMed ID: 19638615
    [Abstract] [Full Text] [Related]

  • 11. Impaired instrumental learning in Spred1-/- mice, a model for a rare RASopathy.
    Borrie SC, Horner AE, Yoshimura A, Legius E, Kopanitsa MV, Brems H.
    Genes Brain Behav; 2021 Jun 28; 20(5):e12727. PubMed ID: 33624414
    [Abstract] [Full Text] [Related]

  • 12. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation.
    Dunzendorfer-Matt T, Mercado EL, Maly K, McCormick F, Scheffzek K.
    Proc Natl Acad Sci U S A; 2016 Jul 05; 113(27):7497-502. PubMed ID: 27313208
    [Abstract] [Full Text] [Related]

  • 13. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1.
    Sasaki A, Taketomi T, Kato R, Saeki K, Nonami A, Sasaki M, Kuriyama M, Saito N, Shibuya M, Yoshimura A.
    Nat Cell Biol; 2003 May 05; 5(5):427-32. PubMed ID: 12717443
    [Abstract] [Full Text] [Related]

  • 14. Interaction of the receptor FGFRL1 with the negative regulator Spred1.
    Zhuang L, Villiger P, Trueb B.
    Cell Signal; 2011 Sep 05; 23(9):1496-504. PubMed ID: 21616146
    [Abstract] [Full Text] [Related]

  • 15. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway.
    Adler V, Qu Y, Smith SJ, Izotova L, Pestka S, Kung HF, Lin M, Friedman FK, Chie L, Chung D, Boutjdir M, Pincus MR.
    Biochemistry; 2005 Aug 16; 44(32):10784-95. PubMed ID: 16086581
    [Abstract] [Full Text] [Related]

  • 16. TC21 and Ras share indistinguishable transforming and differentiating activities.
    Graham SM, Oldham SM, Martin CB, Drugan JK, Zohn IE, Campbell S, Der CJ.
    Oncogene; 1999 Mar 25; 18(12):2107-16. PubMed ID: 10321735
    [Abstract] [Full Text] [Related]

  • 17. SPRED proteins provide a NF-ty link to Ras suppression.
    McClatchey AI, Cichowski K.
    Genes Dev; 2012 Jul 15; 26(14):1515-9. PubMed ID: 22802525
    [Abstract] [Full Text] [Related]

  • 18. Identification of five novel SPRED1 germline mutations in Legius syndrome.
    Laycock-van Spyk S, Jim HP, Thomas L, Spurlock G, Fares L, Palmer-Smith S, Kini U, Saggar A, Patton M, Mautner V, Pilz DT, Upadhyaya M.
    Clin Genet; 2011 Jul 15; 80(1):93-6. PubMed ID: 21649642
    [No Abstract] [Full Text] [Related]

  • 19. Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities.
    Gilbert-Dussardier B, Briand-Suleau A, Laurendeau I, Bilan F, Cavé H, Verloes A, Vidaud M, Vidaud D, Pasmant E.
    Orphanet J Rare Dis; 2016 Jul 22; 11(1):101. PubMed ID: 27450488
    [Abstract] [Full Text] [Related]

  • 20. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
    Messiaen L, Yao S, Brems H, Callens T, Sathienkijkanchai A, Denayer E, Spencer E, Arn P, Babovic-Vuksanovic D, Bay C, Bobele G, Cohen BH, Escobar L, Eunpu D, Grebe T, Greenstein R, Hachen R, Irons M, Kronn D, Lemire E, Leppig K, Lim C, McDonald M, Narayanan V, Pearn A, Pedersen R, Powell B, Shapiro LR, Skidmore D, Tegay D, Thiese H, Zackai EH, Vijzelaar R, Taniguchi K, Ayada T, Okamoto F, Yoshimura A, Parret A, Korf B, Legius E.
    JAMA; 2009 Nov 18; 302(19):2111-8. PubMed ID: 19920235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.